Zobrazeno 1 - 10 of 21 pro vyhledávání: '"Eduard Krishtopaytis"'
1
Vedolizumab has no effect on the course of non-alcoholic fatty liver disease: A retrospective cohort analysis
Autor: Prabhat Kumar, Ashraf Almomani, Somtochukwu Onwuzo, Antoine Boustany, Eduard Krishtopaytis, Dana Alshaikh, Almaza Albakri, Motasem Alkhayyat, Tareq Kiwan, Imad Asaad
Publikováno v: Journal of Clinical and Experimental Gastroenterology. 2:14-18
Background and Aim: Non-Alcoholic Fatty Liver Disease (NAFLD) is the commonest cause of chronic liver disease and is a leading cause of liver transplantation in the United States, with no approved medication to halt or reverse its progression. Recent
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6733ea72dcc98bc93e0b8c949ad6b4f8
https://doi.org/10.46439/gastro.2.013
Zobrazit plný text záznamu
2
Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature
Autor: Ashraf Almomani, Prabhat Kumar, Somtochukwu Onwuzo, Antoine Boustany, Eduard Krishtopaytis, Asif Hitawala, Dana Alshaikh, Almaza Albakri, Leen Hussein, Ebrahim Hussein, Imad Asaad
Publikováno v: Journal of gastroenterology and hepatologyReferences.
Nonalcoholic fatty liver disease (NAFLD) is linked to obesity and metabolic syndrome conditions. However, a subset of NAFLD patients express a normal or low body mass index (lean NAFLD [L-NAFLD]). Our aim is to compare the prevalence of L-NAFLD to th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6d81baf08185631e49461b0500a20a1
https://pubmed.ncbi.nlm.nih.gov/36328950
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje